<?xml version="1.0" encoding="UTF-8"?>
<p>One pathway for macrolide immunomodulation is through binding to macrophilin‐12 inhibiting calcineurin and thus T cell activation, via the same mechanism as tacrolimus,
 <xref rid="rmv2163-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> with consequent downstream inhibition of many immune cells including eosinophils and basophils.
 <xref rid="rmv2163-bib-0068" ref-type="ref">
  <sup>68</sup>
 </xref> Macrolides also inhibit mammalian target of rapamycin (mTOR) activity, also important in T cell activation and granulocyte differentiation,
 <xref rid="rmv2163-bib-0115" ref-type="ref">
  <sup>115</sup>
 </xref> suppressing cell proliferation and CD4 + T cell cytokine secretion.
 <xref rid="rmv2163-bib-0116" ref-type="ref">
  <sup>116</sup>
 </xref> A third pathway modulated by macrolides is activity of the transcription factors NFκB and AP‐1. AZM suppresses p65, a component of NFκB
 <xref rid="rmv2163-bib-0117" ref-type="ref">
  <sup>117</sup>
 </xref> and attenuates NFκB activation in lung epithelial cells.
 <xref rid="rmv2163-bib-0118" ref-type="ref">
  <sup>118</sup>
 </xref> This inhibition reduces epithelial cell IL‐8 production,
 <xref rid="rmv2163-bib-0067" ref-type="ref">
  <sup>67</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0118" ref-type="ref">
  <sup>118</sup>
 </xref> stromal cell proliferation
 <xref rid="rmv2163-bib-0066" ref-type="ref">
  <sup>66</sup>
 </xref> and macrophage expression of IL‐12p40
 <xref rid="rmv2163-bib-0119" ref-type="ref">
  <sup>119</sup>
 </xref> and, indirectly, IL‐1β.
 <xref rid="rmv2163-bib-0065" ref-type="ref">
  <sup>65</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0092" ref-type="ref">
  <sup>92</sup>
 </xref>
</p>
